Teva Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Pharma (TEVA) Gains 7.5% Following Results
February 12, 2020 9:33 AM ESTTeva Pharma (NYSE: TEVA) gains 7.5% off the open following results.
... MoreUPDATE: Teva Pharma (TEVA) Tops Q4 EPS by 1c, Offers FY20 Guidance
February 12, 2020 7:01 AM EST(Updated - February 12, 2020 7:05 AM EST)
Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.62, $0.01 better than the analyst estimate of $0.61. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.35 billion.
2020 business outlook:
Revenues are... More
